Mahatme Sandesh 4

What Happened

• Mahatme Sandesh, a director of CRISPR Therapeutics AG (CRSP), was granted 13,000 derivative awards on 2026-06-05. The Form 4 reports an acquisition amount of $0.00 for these units, indicating they are compensation awards (derivative options/awards), not an open-market purchase or sale. No immediate cash changed hands and no shares were sold.

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-09 (timely filing within SEC two-business-day window).
• Reported units: 13,000 (transaction code A = Grant/Award/Other acquisition).
• Reported price: $0.00 (award/grant); treated as derivative (options) per filing.
• Shares owned after transaction: not reported in the provided excerpt.
• Footnote: Options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month after the grant date; first installment vests June 30, 2026; final installment vests on the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting.
• No 10b5-1 plan, cashless exercise, tax-withholding, or late-filing flags noted in the provided details.

Context

• This is a compensation grant (derivative options) to a director, which typically reflects routine equity-based compensation rather than an immediate market bet. The options vest over a short, one-year monthly schedule and will become exercisable as they vest; the filing does not indicate any immediate exercise or sale.